Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2122 • ACR Convergence 2023
Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Jose Antonio Parra³, Virginia Portilla⁴, Ricardo Blanco⁵, Miguel A Gonzalez-Gay⁶, Ivan Ferraz Amaro⁷ and Alfonso Corrales⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: The risk of mortality is increased in patients with RA compared to the general population. Different non-invasive surrogate markers of atherosclerosis have been implemented…
Abstract Number: 2138 • ACR Convergence 2023
Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis
K Wysham¹, Hannah Brubeck², Aaron Baraff³, Punyasha Roul⁴, Namrata Singh⁵, James Andrews⁶, Grant Cannon⁷, Gary Kunkel⁸, Ted R Mikuls⁹, Bryant England⁴, Dolores Shoback¹⁰, Patti Katz¹¹, Jose Garcia¹², Ariela Orkaby¹³ and Joshua Baker¹⁴, ¹VA Puget Sound/University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA Puget Sound Seattle, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Washington, Bellevue, WA, ⁶University of Washington, Seattle, WA, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah, Salt Lake City, UT, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ¹⁰San Francisco VA Medical Center, San Francisco, CA, ¹¹University of California San Francisco, San Rafael, CA, ¹²VA Puget Sound Healthcare System, Seattle, WA, ¹³Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Frailty occurs prematurely in RA. Levels of frailty are higher in Veteran populations than civilians1. Frailty has been shown to predict osteoporotic fractures in…
Abstract Number: 2154 • ACR Convergence 2023
Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs
Sebastian Ibanez Vodnizza¹, María Paz Poblete², María Francisca Valenzuela³, María Magdalena Canals², Dominga García² and Carla Jaque³, ¹Clinica Alemana de Santiago / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ²Hospital Padre Hurtado / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ³Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: In Chile, patients with rheumatoid arthritis (RA) can apply to receive state-funded biological or JAK inhibitor treatment if they have failed (defined as a…
Abstract Number: 2171 • ACR Convergence 2023
Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?
Yoshinobu Koyama¹, Yoshiharu Sato², Moe Tokunaga(Sakamoto)³ and Yu Nakai³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: To date, there are no head-to-head clinical trials directly comparing the effects between IL-6i and JAKi on bone destruction in RA. In recent years,…
Abstract Number: 2451 • ACR Convergence 2023
TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank
Karen Costenbader¹, Zhi Yu², Emily G. Oakes³, Michelle Robinette⁴, Mridul Agarwal⁵, Buu Truong⁶, Md Mesbah Uddin⁶, Alexander Bick⁷, Abhishek Niroula⁶, Daniel Solomon³ and Pradeep Natarajan⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Broad Institute; Massachusetts General Hospital, Cambridge, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital; Dana-Farber Cancer Institute, Boston, MA, ⁵Dana-Farber Cancer Institute, Boston, MA, ⁶Broad Institute, Cambridge, MA, ⁷Broad Institute; Vanderbilt University Medical Center, Nashville, TN, ⁸Broad Institute; Massachusetts General Hospital, Boston, MA
Background/Purpose: Clonal hematopoiesis (CH), the clonal expansion of somatically mutated blood cells in people without hematologic malignancy, is found in ~10% of people age ≥…
Abstract Number: 2541 • ACR Convergence 2023
Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity
Joshua Baker¹, James O'Dell², Bryant England², Jon Giles³, Jefferey Newcomb⁴, Michael George¹, Geoffrey Thiele², Larry Moreland⁵, S. Louis Bridges⁶, Jeffrey R Curtis⁷ and Ted R Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Columbia University, New York, NY, ⁴University of Nebraska, Omaha, NE, ⁵University of Colorado, Denver, CO, ⁶Hospital for Special Surgery, New York, NY, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…
Abstract Number: 0029 • ACR Convergence 2023
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts
Nozima Aripova¹, Michael Duryee¹, Carlos Hunter¹, Breanna Butler¹, Amy Nelson¹, Bryant England¹, James O'Dell¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cellular interactions between alveolar macrophages (MΦ) and human lung fibroblasts (HLFs) contribute to excessive pro-inflammatory and pro-fibrotic responses in rheumatoid arthritis interstitial lung disease…
Abstract Number: 0094 • ACR Convergence 2023
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Helena Jonsson¹, Carlos Donado², Erin Theisen², Dominique Jones¹, Aparna Nathan³, Fan Zhang⁴, Accelerating Medicines Partnership (AMP): RA/SLE¹, Soumya Raychaudhuri¹ and Michael Brenner², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴University of Colorado, Aurora, CO
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. While most research has focused on CD4+ T cells, we have found that CD8+…
Abstract Number: 0225 • ACR Convergence 2023
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
Yi-Ming Chen¹, Jun-Pen Chen², Chi-Wei Tseng², CARLOS ENRIQUE TORO GUTIERREZ³, Elena Nikiphorou⁴, Ai Lyn Tan⁵, Arvind Nune⁶, Esha Kadam⁷, Masataka Kuwana⁸, Jessica Day⁹, Sreoshy Saha¹⁰, Tsvetelina Velikova¹¹, James Lilleker¹², CARLO VINICIO CABALLERO¹³, Parikshit Sen¹⁴, Hector Chinoy¹⁵, Rohit Aggarwal¹⁶, Vikas Agarwal¹⁷ and Latika Gupta¹⁸, ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan, ³Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ⁴King's College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ⁷Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Walter and Eliza Hall Institute, Melbourne, Australia, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹²Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. Orcid ID: 0000-0002-9230-4137., Manchester, United Kingdom, ¹³REUMACARIBE IPS, Barranquilla, Colombia, ¹⁴Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁵The University of Manchester, Sale, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Existing studies have shown that disease activity of patients with rheumatoid arthritis (RA) may surge after COVID-19 infection. However, factors associated with disease flares…
Abstract Number: 0387 • ACR Convergence 2023
The Association Between Inflammation, High-Sensitivity Cardiac Troponin T, and Cardiovascular Events in Rheumatoid Arthritis
Brittany Weber¹, Dana Weisenfeld¹, Mary Jeffway¹, Jonathan Coblyn¹, Michael Weinblatt², Nancy Shadick³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 1.5x excess risk of cardiovascular (CV) disease compared to the general population, attributed to chronic inflammation. In…
Abstract Number: 0403 • ACR Convergence 2023
Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis
Courtney Loecker¹, Bryant England², Punyasha Roul², Namrata Singh³, Kaleb Michaud², Lani Zimmerman⁴, Myra Schmaderer⁴, Grant Cannon⁵, Ted R Mikuls⁶, Gary Kunkel⁷, Ariela Orkaby⁸, Joshua Baker⁹ and K Wysham¹⁰, ¹University of Nebraska Medical Center;VA Nebraska-Western Iowa Health Care System, Lincoln, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Nebraska Medical Center, Lincoln, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷VA Salt Lake City & University of Utah, Salt Lake City, UT, ⁸Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty, defined as an increased vulnerability to stressors and adverse health outcomes, is an emerging concept in RA. Active RA disease gives rise to…
Abstract Number: 0420 • ACR Convergence 2023
Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers
Gregory McDermott¹, Keigo Hayashi¹, Matthew Moll¹, Michael Cho¹, Kazuki Yoshida¹, Tracy J. Doyle¹, Gregory Kinney², Paul Dellaripa³, Zachary Wallace⁴, Elizabeth Regan⁵, Gary Hunninghake¹, Edwin Silverman¹, Samuel Ash¹, Raul San Jose Estepar¹, George Washko¹ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado Denver, Denver, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵National Jewish Health, Denver, CO, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Quantitative computed tomography (QCT) methods have been developed to automatically quantify parenchymal lung features on chest CT imaging. There have been limited investigations of…
Abstract Number: 0437 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², K Wysham³, Jean liew⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
Abstract Number: 0454 • ACR Convergence 2023
Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices
Theodore Pincus¹, Nicholas Rodwell² and Rahel Hunter¹, ¹Rush University Medical Center, Chicago, IL, ²University of New South Wales, Sydney, Australia
Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].